Generic Name and Formulations:
Mesalamine 1g; supps.
Indications for CANASA:
Mild-to-moderately active ulcerative proctitis.
Retain supp in rectum for at least 1–3hrs. 1g once daily at bedtime. Treat for 3–6 weeks.
Sulfasalazine or aspirin allergy. Renal or hepatic impairment. Evaluate renal function before starting and periodically during therapy. Monitor for acute intolerance syndrome; discontinue if suspected. May stain clothes. Elderly. Pregnancy. Nursing mothers.
Concomitant nephrotoxic agents (eg, NSAIDs) may increase risk of renal effects; monitor. Concomitant azathioprine or 6-mercaptopurine may increase risk of blood disorders; if unavoidable, monitor CBCs and platelets. May interfere with measurements by liquid chromatography of urinary normetanephrine; consider other alternative assay.
Dizziness, rectal pain, fever, rash, acne, colitis, headache, flatulence, abdominal pain, diarrhea, nausea; mesalamine-induced acute intolerance syndrome, hypersensitivity reactions (including myocarditis, pericarditis, pneumonitis, hematologic abnormalities), renal or hepatic failure.
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D